In the article by Lu and Daugherty, which appeared in the March 2015 issue of the journal (Arterioscler Thromb Vasc Biol. 2015;35:485–491. DOI: 10.1161/ATVBAHA.115.305380), a correction was needed.
In the section “Proprotein Convertase Subtilisin/Kexin Type 9,” the last 2 sentences of the first paragraph have been revised as follows to show that there was an increased expression of PCSK6, not PCSK9, in the fibrous caps of human atherosclerosis: “Findings in human studies have led to the development of PCSK9 inhibitors to reduce plasma cholesterol concentrations and risks for cardiovascular events.52 In addition to PCSK9, profiling of carotid atherosclerosis from a human biobank using microarray technique found increased PCSK6 (a PCSK family member apart from PCSK9) mRNA abundance in fibrous caps of symptomatic carotid atherosclerotic lesions.53” As a result, references 52 and 53 have been renumbered to be 53 and 52, respectively.
The authors apologize for the error.
The online version of the article has been corrected and is available at http://atvb.ahajournals.org/content/35/3/485.
- © 2016 American Heart Association, Inc.